CD83+PD-L1+ Mesenchymal Stem Cell Induction for Consistent Immunosuppression

Solution Overview

Problem

Existing mesenchymal stem cell (MSC) therapies for inflammatory and immune-related diseases exhibit significant individual variability due to heterogeneity and dependence on microenvironmental stimulation for inflammatory/immune regulatory functions, leading to inconsistent clinical efficacy.

Innovation Solution

The development of CD83+ and CD83+PD-L1+ mesenchymal stem cells, obtained through magnetic sorting and lentiviral gene transduction, which are induced to enhance anti-inflammatory and immunosuppressive functions using immune factors, allowing for targeted therapeutic applications in autoimmune and inflammatory diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional MSC transplantation is used for treating inflammatory and immune-related diseases, then the therapy can potentially restore immune balance and promote tissue repair, but the clinical efficacy shows huge individual differences and inconsistent results

Engineering Contradiction:

Improveclinical efficacy consistencyVSAvoidindividual response variability

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the key parameter of MSC surface marker expression by inducing differentiation towards dendritic cell phenotype, specifically upregulating CD83 and PD-L1 markers. This parameter change transforms conventional MSCs into cells with enhanced immunosuppressive functions, thereby improving reliability of clinical efficacy while reducing individual response variability

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent applies preliminary action by pre-differentiating MSCs ex vivo before transplantation. The cells are cultured under specific conditions with immune factors (IFN-γ, TNF-α, IL-1β) to induce dendritic cell-like phenotype and enhance immunosuppressive marker expression prior to administration, ensuring consistent therapeutic effect across different patients

Inventive Principle:

Principle #10Preliminary action

2Productivity

If MSCs are used in natural state for tissue repair, then they maintain pluripotent stem cell properties, but they lack constitutive inflammatory/immune regulatory functions

Engineering Contradiction:

Improveimmune regulatory functionVSAvoidcell preparation process

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent applies preliminary action by pre-differentiating MSCs ex vivo before transplantation. The cells are cultured under specific conditions with immune factors (IFN-γ, TNF-α, IL-1β) to induce dendritic cell-like phenotype and enhance immunosuppressive marker expression prior to administration, ensuring consistent therapeutic effect across different patients

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent changes the key parameter of MSC surface marker expression by inducing differentiation towards dendritic cell phenotype, specifically upregulating CD83 and PD-L1 markers. This parameter change transforms conventional MSCs into cells with enhanced immunosuppressive functions, thereby improving reliability of clinical efficacy while reducing individual response variability

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The CD83+ and CD83+PD-L1+ MSCs demonstrate enhanced secretion of anti-inflammatory and immunosuppressive factors, improving clinical efficacy in treating conditions like rheumatoid arthritis and sepsis by reducing mortality and inflammatory responses.

Implementation Method 1

sorting and obtaining immunosuppressive or anti-inflammatory function-prone natural CD83+ MSCs/CD83+ overexpressed MSCs by magnetic beads coupled with anti-CD83 antibodies and flow sorting technology

Methodology Applied

Scientific EffectMagnetic separation: Magnetism

Implementation Method 2

or lentiviral gene transduction technology

Methodology Applied

Scientific EffectViral transduction:

Implementation Method 3

the MSCs need to be stimulated by inflammatory factors such as IFN-γ, TNF-α, and IL-1β to undergo immunosuppressive or anti-inflammatory reprogramming, and then express anti-inflammatory mediators or receptors such as PD-L1, IDO, and IL-10

Methodology Applied

Scientific EffectCellular differentiation and reprogramming:

Data Source

PatentUS20250262246A1CD83+, CD83+PD-l1+ mesenchymal stem cells and preparation methods and use thereof

Publication Date: 2025.08.21 CHINESE PEOPLES LIBERATION ARMY ARMY SPECIAL MEDICAL CENTER

AI summary

Use of CD83+ mesenchymal stem cells/CD83+ overexpressed mesenchymal stem cells in the preparation of drugs for preventing/treating at least one of autoimmune disease or inflammatory-related disease is provided. The CD83+ mesenchymal stem cells/CD83+ overexpressed mesenchymal stem cells are capable of increasing the secretion of at least one of anti-inflammatory factor or immunosuppressive factor. Immunosuppressive or anti-inflammatory function-prone CD83+ mesenchymal stem cells/CD83+ overexpressed mesenchymal stem cells and a preparation method for immunosuppressive or anti-inflammatory function enhanced CD83+ PD-L1+ mesenchymal stem cells are also provided. The immunosuppressive or anti-inflammatory function enhanced CD83+PD-L1+-MSCs can significantly reduce the mortality rate and inflammatory response of the sepsis in the treatment of sepsis and can also significantly improve the clinical symptom of the arthritis in mice in the treatment of collagen induced arthritis. Anti-inflammatory CD83+PD-L1+-MSCs induction kit can be further developed based on an induction process of anti-inflammatory CD83+PD-L1+-MSCs, which can be readily popularized for application.